AR115769A1 - Moléculas de unión a mesotelina y cd137 - Google Patents
Moléculas de unión a mesotelina y cd137Info
- Publication number
- AR115769A1 AR115769A1 ARP190101973A ARP190101973A AR115769A1 AR 115769 A1 AR115769 A1 AR 115769A1 AR P190101973 A ARP190101973 A AR P190101973A AR P190101973 A ARP190101973 A AR P190101973A AR 115769 A1 AR115769 A1 AR 115769A1
- Authority
- AR
- Argentina
- Prior art keywords
- seq
- nos
- antibody molecule
- binding site
- antigen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente se refiere a las moléculas de anticuerpo que se unen tanto a mesotelina (MSLN) como CD137. Las moléculas de anticuerpo comprenden un sitio de unión basado en CDR para MSLN y un sitio de unión al antígeno CD137 ubicado en un dominio constante de la molécula de anticuerpo. Las moléculas de anticuerpo se aplican por ejemplo en el tratamiento del cáncer. Reivindicación 1: Una molécula de anticuerpo que se une a mesotelina (MSLN) y CD137, que comprende (a) un sitio de unión al antígeno basado en la región determinante de complementariedad (CDR) MSLN; y (b) un sitio de unión al antígeno CD137 ubicado en un dominio CH3 de la molécula de anticuerpo; donde el sitio de unión al antígeno basado en CDR comprende las CDR 1 - 6 expuestas en: (i) SEQ ID Nº 42, 33, 44, 20, 22, y 80, respectivamente [FS28-256-271]; (ii) SEQ ID Nº 14, 16, 27, 20, 22 y 24, respectivamente [FS28-024-052]; (iii) SEQ ID Nº 42, 33, 44, 20, 22 y 40, respectivamente [FS28-256-021]; (iv) SEQ ID Nº 42, 33, 44, 20, 22, 37, respectivamente [FS28-256-012]; (v) SEQ ID Nº 50, 33, 52, 20, 22 y 40, respectivamente [FS28-256-023]; (vi) SEQ ID Nº 42, 33, 44, 20, 22 y 41, respectivamente [FS28-256-024]; (vii) SEQ ID Nº 50, 33, 52, 20, 22 y 41, respectivamente [FS28-256-026]; (viii) SEQ ID Nº 42, 33, 44, 20, 22, y 80, respectivamente [FS28-256-027]; (ix) SEQ ID Nº 38, 33, 35, 20, 22, y 40, respectivamente [FS28-256-001]; (x) SEQ ID Nº 38, 33, 35, 20, 22, y 41 respectivamente [FS28-256-005]; (xi) SEQ ID Nº 46, 33, 48, 20, 22 y 37, respectivamente [FS28-256-014]; (xii) SEQ ID Nº 50, 33, 52, 20, 22 y 37, respectivamente [FS28-256-018]; (xiii) SEQ ID Nº 31, 33, 35, 20, 22 y 37, respectivamente [FS28-256]; (xiv) SEQ ID Nº 14, 16, 25, 20, 22 y 24, respectivamente [FS28-024-051]; SEQ ID Nº 14, 16, 29, 20, 22 y 24, respectivamente [FS28-024-053]; o (xvi) SEQ ID Nº 14, 16, 18, 20, 22 y 24, respectivamente [FS28-024], y donde el sitio de unión al antígeno CD137 comprende una primera secuencia y una segunda secuencia ubicada en los bucles estructurales AB y EF del dominio CH3, respectivamente, donde la primera y segunda secuencia tienen la secuencia expuesta en las SEQ ID Nº 10 y 11 [FS22-172-003], respectivamente. Reivindicación 14: Una molécula o moléculas de ácido nucleico que codifican la molécula de anticuerpo de acuerdo con cualquiera de las reivindicaciones precedentes. Reivindicación 17: Un procedimiento de producir la molécula de anticuerpo de acuerdo con cualquiera de las reivindicaciones 1 a 13 que comprende cultivar las células huésped recombinantes de la reivindicación 16 en condiciones para la producción de la molécula de anticuerpo. Reivindicación 18: Una composición farmacéutica que comprende la molécula de anticuerpo de acuerdo con cualquiera de las reivindicaciones 1 a 13 y un excipiente farmacéuticamente aceptable.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1811450.4A GB201811450D0 (en) | 2018-07-12 | 2018-07-12 | Mesothelin and CD137 binding molecules |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR115769A1 true AR115769A1 (es) | 2021-02-24 |
Family
ID=63273224
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP190101973A AR115769A1 (es) | 2018-07-12 | 2019-07-12 | Moléculas de unión a mesotelina y cd137 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20210309753A1 (es) |
| EP (1) | EP3820894A1 (es) |
| JP (2) | JP7360441B2 (es) |
| KR (1) | KR20210030925A (es) |
| CN (1) | CN112437776B (es) |
| AR (1) | AR115769A1 (es) |
| AU (1) | AU2019303081A1 (es) |
| BR (1) | BR112021000396A2 (es) |
| CA (1) | CA3103173A1 (es) |
| GB (1) | GB201811450D0 (es) |
| IL (1) | IL280007A (es) |
| MX (1) | MX2021000397A (es) |
| SG (1) | SG11202011960XA (es) |
| TW (1) | TWI839365B (es) |
| WO (1) | WO2020011976A1 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201612520D0 (en) | 2016-07-19 | 2016-08-31 | F-Star Beta Ltd | Binding molecules |
| WO2019121906A1 (en) | 2017-12-19 | 2019-06-27 | F-Star Beta Limited | Specific pd-l1 binding sequences inserted in a ch3 domain |
| MA52366A (fr) | 2018-04-25 | 2021-03-03 | Prometheus Biosciences Inc | Anticorps anti-tl1a optimisés |
| GB201811408D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | CD137 Binding Molecules |
| WO2020081895A2 (en) * | 2018-10-18 | 2020-04-23 | The Scripps Research Institute | Siv envelope trimer |
| AU2020371725A1 (en) | 2019-10-24 | 2022-05-26 | Cedars-Sinai Medical Center | Humanized antibodies to TNF-like ligand 1A (TL1A) and uses thereof |
| WO2024039672A2 (en) * | 2022-08-15 | 2024-02-22 | Dana-Farber Cancer Institute, Inc. | Antibodies against msln and methods of use thereof |
| WO2024042105A1 (en) | 2022-08-26 | 2024-02-29 | Merck Patent Gmbh | Cancer treatment comprising an anti-msln/cd137 antibody and a chemotherapeutic |
| WO2024042104A1 (en) | 2022-08-26 | 2024-02-29 | Merck Patent Gmbh | Combination cancer treatment comprising an anti-msln/cd137 antibody and pd-1/pd-l1 inhibitor |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| WO2000073346A1 (en) | 1999-05-27 | 2000-12-07 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Immunoconjugates having high binding affinity |
| US7288638B2 (en) | 2003-10-10 | 2007-10-30 | Bristol-Myers Squibb Company | Fully human antibodies against human 4-1BB |
| EA018897B1 (ru) | 2005-01-05 | 2013-11-29 | Ф-Стар Биотехнологише Форшунгс- Унд Энтвиклунгсгез.М.Б.Х. | Молекулы иммуноглобулина, содержащие модифицированные участки структурных петель, обладающие свойством связывания, и способ их получения |
| KR101559599B1 (ko) | 2007-11-26 | 2015-10-12 | 바이엘 인텔렉쳐 프로퍼티 게엠베하 | 항-메소텔린 항체 및 이의 용도 |
| EP2113255A1 (en) | 2008-05-02 | 2009-11-04 | f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. | Cytotoxic immunoglobulin |
| EP2900695B1 (en) * | 2012-09-27 | 2018-01-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Mesothelin antibodies and methods for eliciting potent antitumor activity |
| KR101782487B1 (ko) * | 2015-09-24 | 2017-09-27 | 재단법인 목암생명과학연구소 | 신규 항-메소텔린 항체 및 이를 포함하는 조성물 |
| EP3445788B1 (en) * | 2016-04-22 | 2022-01-19 | Alligator Bioscience AB | Novel bispecific polypeptides against cd137 |
| TW201806972A (zh) * | 2016-05-27 | 2018-03-01 | 美商艾伯維生物醫療股份有限公司 | 雙特異性結合蛋白 |
| CN107523546A (zh) * | 2016-06-20 | 2017-12-29 | 上海细胞治疗研究院 | 一种高效稳定表达抗体的nk细胞及其用途 |
-
2018
- 2018-07-12 GB GBGB1811450.4A patent/GB201811450D0/en not_active Ceased
-
2019
- 2019-07-12 TW TW108124775A patent/TWI839365B/zh active
- 2019-07-12 WO PCT/EP2019/068817 patent/WO2020011976A1/en active Application Filing
- 2019-07-12 JP JP2021500386A patent/JP7360441B2/ja active Active
- 2019-07-12 EP EP19742323.9A patent/EP3820894A1/en active Pending
- 2019-07-12 AR ARP190101973A patent/AR115769A1/es unknown
- 2019-07-12 AU AU2019303081A patent/AU2019303081A1/en active Pending
- 2019-07-12 BR BR112021000396-7A patent/BR112021000396A2/pt unknown
- 2019-07-12 US US17/259,634 patent/US20210309753A1/en active Pending
- 2019-07-12 MX MX2021000397A patent/MX2021000397A/es unknown
- 2019-07-12 CA CA3103173A patent/CA3103173A1/en active Pending
- 2019-07-12 KR KR1020217000265A patent/KR20210030925A/ko unknown
- 2019-07-12 SG SG11202011960XA patent/SG11202011960XA/en unknown
- 2019-07-12 CN CN201980046873.7A patent/CN112437776B/zh active Active
-
2021
- 2021-01-07 IL IL280007A patent/IL280007A/en unknown
-
2023
- 2023-09-29 JP JP2023169048A patent/JP2023178323A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| SG11202011960XA (en) | 2020-12-30 |
| MX2021000397A (es) | 2021-05-27 |
| JP2023178323A (ja) | 2023-12-14 |
| KR20210030925A (ko) | 2021-03-18 |
| JP2021524269A (ja) | 2021-09-13 |
| IL280007A (en) | 2021-03-01 |
| CN112437776B (zh) | 2024-07-26 |
| TW202012448A (zh) | 2020-04-01 |
| CN112437776A (zh) | 2021-03-02 |
| AU2019303081A1 (en) | 2021-03-11 |
| TWI839365B (zh) | 2024-04-21 |
| WO2020011976A1 (en) | 2020-01-16 |
| US20210309753A1 (en) | 2021-10-07 |
| GB201811450D0 (en) | 2018-08-29 |
| EP3820894A1 (en) | 2021-05-19 |
| BR112021000396A2 (pt) | 2021-04-06 |
| JP7360441B2 (ja) | 2023-10-12 |
| CA3103173A1 (en) | 2020-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR115769A1 (es) | Moléculas de unión a mesotelina y cd137 | |
| AR110101A1 (es) | Miembros de unión (2) | |
| AR109659A2 (es) | Anticuerpos inhibidores de la dimerización del c-met y usos de los mismos | |
| PE20181952A1 (es) | Anticuerpos anti-ll-33, composiciones, metodos y usos de los mismos | |
| HRP20180269T1 (hr) | Anti-cd40 protutijela, upotrebe i postupci | |
| AR111630A1 (es) | ANTICUERPOS ANTI-SIRPa | |
| AR105026A1 (es) | ANTICUERPOS MADURADOS POR AFINIDAD Y HUMANIZADOS PARA FcRH5 Y MÉTODOS PARA SU USO | |
| PE20190120A1 (es) | Moleculas de union a bcma y metodos de uso de las mismas | |
| AR102918A1 (es) | Anticuerpos anti-cd79b y métodos de uso | |
| AR106184A1 (es) | Proteínas de unión a pd-1 y sus métodos de uso | |
| PE20231958A1 (es) | Moleculas de union a pd-1 y metodos de uso de las mismas | |
| RU2017121326A (ru) | Общие легкие цепи и способы их применения | |
| AR117911A2 (es) | Anticuerpo anti-158p1d7 o fragmento de unión a antígeno del mismo, conjugado fármaco-anticuerpo, composición farmacéutica y sus usos | |
| AR109264A1 (es) | Proteínas de unión semejantes a anticuerpo biespecíficas que se unen específicamente a cd3 y cd123 | |
| RU2017122014A (ru) | Антитела к c10orf54 и их применения | |
| AR076662A1 (es) | Anticuerpos anti-egfl7 humanizados y metodos de uso de los mismos | |
| PE20201255A1 (es) | Anticuerpos y conjugados de anticuerpo-farmaco especificos para cd123 y usos de los mismos | |
| CA2699834A1 (en) | Improved anti-il-6 receptor antibody | |
| PE20220575A1 (es) | Anticuerpos multiespecificos de cadena pesada que se unen a cd22 y cd3 | |
| PE20210554A1 (es) | Anticuerpos anti-cxcr5 y composiciones y usos de los mismos | |
| BR112022009570A2 (pt) | Anticorpo anti-¿v¿6 isolado ou fragmento de ligação ao antígeno, conjugado anticorpo-fármaco, ácido nucleico, vetor, célula hospedeira, métodos para produção de um anticorpo anti-¿v¿6 ou fragmento de ligação ao antígeno, para produção de um conjugado anticorpo anti-¿v¿6-fármaco e para tratamento de câncer em um indivíduo, e, composição farmacêutica | |
| PE20220392A1 (es) | Moleculas de union a claudina-6 y usos de las mismas | |
| CY1121249T1 (el) | Αντισωμα εναντι του ειδικου προστατικου αντιγονου βλαστικου κυτταρου και χρησεις αυτου | |
| AR109857A1 (es) | Anticuerpos anti-chikv y usos de éstos | |
| JP2018528759A5 (es) |